Goodman Financial Corp Buys 137,772 Shares of Pfizer Inc. $PFE

Goodman Financial Corp raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 28.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 621,214 shares of the biopharmaceutical company’s stock after buying an additional 137,772 shares during the quarter. Pfizer comprises 2.9% of Goodman Financial Corp’s portfolio, making the stock its 14th largest holding. Goodman Financial Corp’s holdings in Pfizer were worth $15,468,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Brighton Jones LLC grew its stake in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC lifted its stake in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 2,087 shares in the last quarter. United Bank boosted its holdings in Pfizer by 12.4% in the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after purchasing an additional 6,415 shares during the period. AXQ Capital LP purchased a new position in shares of Pfizer during the 2nd quarter valued at $311,000. Finally, Cozad Asset Management Inc. grew its position in shares of Pfizer by 4.1% during the 2nd quarter. Cozad Asset Management Inc. now owns 38,086 shares of the biopharmaceutical company’s stock valued at $923,000 after purchasing an additional 1,509 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Down 1.6%

Shares of PFE opened at $26.98 on Monday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.94. The firm has a market cap of $153.41 billion, a price-to-earnings ratio of 19.84 and a beta of 0.47. The firm has a 50 day moving average price of $26.68 and a 200-day moving average price of $25.61. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.57 by $0.09. The company had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.63 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Topline Phase 3 win for TALZENNA (talazoparib) + XTANDI: the TALAPRO-3 study met its primary endpoint, showing a significant delay in radiographic progression-free survival in HRR‑mutated metastatic castration‑sensitive prostate cancer — a meaningful commercial and clinical win for Pfizer’s oncology franchise. TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer
• Positive Sentiment: Additional oncology progress: a Phase II study of atirmociclib in second‑line metastatic breast cancer hit its primary endpoint, supporting pipeline diversification beyond vaccines and COVID-era revenues. PFE’s Atirmociclib 2L Breast Cancer Study Hits Goal, Aid Pipeline Push
• Positive Sentiment: Analyst interest/upgrade flow: recent analyst upgrades and a bullish HSBC forecast have lent buy‑side support and renewed attention to Pfizer’s valuation and upside potential. Pfizer (NYSE:PFE) Stock Price Up 3.2% Following Analyst Upgrade
• Neutral Sentiment: Pfizer-linked investment activity: Earendil Labs closed a $787M financing that included participation from a biotech development fund associated with Pfizer — a sign of strategic R&D/venture exposure but not an immediate earnings driver. Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development
• Neutral Sentiment: Market commentary and valuation focus: several recent pieces reassess Pfizer’s valuation and compare it to peers (e.g., Moderna), keeping the stock in investors’ screens but creating mixed sentiment around near‑term upside. Reassessing Pfizer (PFE) Valuation As Shares Trade Around Recent Levels
• Negative Sentiment: Unsolicited mini‑tender offer: Tutanota LLC filed a conditional mini‑tender to buy up to 1M Pfizer shares at $32 — Pfizer has advised shareholders to reject it. The offer is unlikely to be material but can create short‑term trading noise. Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

Analysts Set New Price Targets

A number of brokerages recently issued reports on PFE. HSBC increased their price objective on Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. Zacks Research upgraded Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. Citigroup started coverage on Pfizer in a report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price target on the stock. TD Cowen reiterated a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. Finally, Barclays began coverage on Pfizer in a report on Thursday, February 19th. They set an “underweight” rating and a $25.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $28.14.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.